Table 1. Serotype specific carriage rate from 2014–18 in Matiari, Pakistan.
| Serotype | 2013 (Baseline)α | 2014–15 | 2015–16 | 2016–17 | 2017–18 | p-value |
|---|---|---|---|---|---|---|
| N = 225 | N = 771 | N = 780 | N = 779 | N = 810 | ||
| PCV10-types | n (%) | n (%) | n (%) | n (%) | n (%) | |
| 1 | - | 1 (0.1) | 1 (0.1) | 0 (0) | 0 (0) | 0.562 |
| 4 | - | 2 (0.3) | 0 (0) | 3 (0.4) | 5 (0.6) | 0.174 |
| 5 | - | 1 (0.1) | 0 (0) | 0 (0) | 0 (0) | 0.380 |
| 6B * | 7 (3.1) | 26 (3.4) | 26 (3.3) | 23 (3.0) | 11 (1.4) | 0.043 |
| 9V/9A * | 9 (4.0) | 22 (2.9) | 9 (1.2) | 6 (0.8) | 5 (0.6) | <0.001 |
| 14 | 8 (3.6) | 12 (1.6) | 12 (1.5) | 7 (0.9) | 11 (1.4) | 0.646 |
| 18C/18F/18B/18A | 5 (2.2) | 10 (1.3) | 20 (2.6) | 7 (0.9) | 13 (1.6) | 0.057 |
| 19F * | 8 (3.6) | 19 (2.5) | 19 (2.4) | 8 (1.0) | 9 (1.1) | 0.033 |
| 23F | 23 (10.2) | 31 (4.0) | 15 (1.9) | 21 (2.7) | 24 (3.0) | 0.102 |
| PCV-13 specific types | ||||||
| 3 | - | 1 (0.1) | 1 (0.1) | 1 (0.1) | 1 (0.1) | 1.0 |
| 6A | 19 (8.4) | 50 (6.5) | 56 (7.2) | 53 (6.8) | 42 (5.2) | 0.391 |
| 19A * | 16 (7.1) | 31 (4.0) | 23 (2.9) | 43 (5.5) | 55 (6.8) | 0.002 |
| NVT serotypes | ||||||
| 13 * | 1 (0.4) | 33 (4.3) | 20 (2.6) | 18 (2.3) | 16 (2.0) | 0.027 |
| 20 | - | 0 (0) | 1 (0.1) | 4 (0.5) | 3 (0.4) | 0.176 |
| 21 * | 3 (1.3) | 9 (1.2) | 9 (1.2) | 9 (1.2) | 23 (2.8) | 0.013 |
| 31 | - | 1 (0.1) | 2 (0.3) | 2 (0.3) | 1 (0.1) | 0.874 |
| 34 | 2 (0.9) | 19 (2.5) | 27 (3.5) | 16 (2.1) | 15 (1.9) | 0.167 |
| 10A * | 7 (3.1) | 25 (3.2) | 44 (5.6) | 55 (7.1) | 43 (5.3) | 0.010 |
| 10F/10C/33C | 1 (0.4) | 15 (1.9) | 11 (1.4) | 8 (1.0) | 8 (1.0) | 0.319 |
| 11A/11D | 2 (0.9) | 30 (3.9) | 30 (3.8) | 32 (4.1) | 39 (4.8) | 0.752 |
| 12F/12A/44/46 | 1 (0.4) | 6 (0.8) | 9 (1.2) | 3 (0.4) | 2 (0.3) | 0.099 |
| 15B/15C | 6 (2.7) | 43 (5.6) | 35 (4.5) | 55 (7.1) | 36 (4.4) | 0.072 |
| 15F/15A * | 4 (1.8) | 12 (1.6) | 3 (0.4) | 15 (1.9) | 8 (0.1) | 0.031 |
| 16F | 1 (0.4) | 21 (2.7) | 17 (2.2) | 22 (2.8) | 13 (1.6) | 0.345 |
| 17F | 6 (2.7) | 15 (1.9) | 11 (1.4) | 9 (1.2) | 17 (2.1) | 0.414 |
| 22F/22A | 1 (0.4) | 7 (0.9) | 3 (0.4) | 7 (0.9) | 2 (0.2) | 0.199 |
| 23A | 1 (0.4) | 7 (0.9) | 6 (0.8) | 9 (1.2) | 11 (1.4) | 0.668 |
| 23B | 5 (2.2) | 20 (2.6) | 21 (2.7) | 9 (1.2) | 18 (2.2) | 0.141 |
| 24F/24A/24B | 6 (2.7) | 5 (0.6) | 6 (0.8) | 3 (0.4) | 10 (1.2) | 0.264 |
| 33F/33A/37 | - | 6 (0.8) | 6 (0.8) | 10 (1.3) | 8 (1.0) | 0.697 |
| 35A/35C/42 | - | 4 (0.5) | 10 (1.3) | 8 (1.0) | 9 (1.1) | 0.464 |
| 35B | 5 (2.2) | 28 (3.6) | 20 (2.6) | 28 (3.6) | 24 (3.0) | 0.567 |
| 35F/47F | 1 (0.4) | 5 (0.6) | 0 (0.0) | 2 (0.3) | 1 (0.1) | 0.064 |
| 38/25F/25A | - | 5 (0.6) | 2 (0.3) | 5 (0.6) | 7 (0.9) | 0.471 |
| 6C | 2 (0.9) | 11 (1.4) | 3 (0.4) | 5 (0.6) | 11 (1.4) | 0.082 |
| 6D | 8 (3.6) | 10 (1.3) | 11 (1.4) | 7 (0.9) | 9 (1.1) | 0.799 |
| 7C/7B/40 * | 5 (2.2) | 10 (1.3) | 25 (3.2) | 7 (0.9) | 10 (1.2) | 0.001 |
| 9N/9L * | 6 (2.7) | 21 (2.7) | 11 (1.4) | 4 (0.5) | 4 (0.5) | <0.001 |
| 2 | - | 1 (0.1) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0.380 |
| 8 | - | 3 (0.4) | 1 (0.1) | 1 (0.1) | 1 (0.1) | 0.552 |
| All PCV10-types * (VT) | 60 (26.7) | 124 (16.1) | 102 (13.1) | 75 (9.6) | 78 (9.6) | <0.001 |
| Non-PCV10-types(NVT) | 165 (73.3) | 499 (64.7) | 473 (60.6) | 508 (65.2) | 510 (63.0) | 0.927 |
| Non-PCV13-types * | 130 (57.7) | 417 (54.0) | 415 (53.2) | 389 (49.9) | 393 (48.5) | <0.001 |
| Non-typeables | 8 (3.6) | 45 (5.8) | 49 (6.3) | 58 (7.4) | 63 (7.8) | 0.083 |
*p-value for trend <0.05
α Pre-vaccine introduction data (2013) is not included in the trend analysis.